Cognition Therapeutics, Inc. (CGTX) vs Neuraxis, Inc. (NRXS)

Cognition Therapeutics, Inc. and Neuraxis, Inc. are both Biotechnology companies. Cognition Therapeutics, Inc. and Neuraxis, Inc. are of similar size ($97.3M and $90.7M). Cognition Therapeutics, Inc. has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Cognition Therapeutics, Inc. leads on 8 and Neuraxis, Inc. on 4.

Valuation

Metric CGTX NRXS Biotechnology median
P/E n/m n/m 7.88
P/S n/m 17.24 11.47
P/B 2.58 13.61 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 15.68 10.73
Earnings yield (18.09%) (10.32%) (28.84%)
Free cash flow yield (20.77%) (6.31%) (23.03%)

Profitability

Metric CGTX NRXS Biotechnology median
Gross margin 0.00% 85.56% 65.16%
Operating margin 0.00% (144.51%) 0.00%
Net margin 0.00% (159.01%) 0.00%
Free cash flow margin 0.00% (106.10%) 0.00%
Return on equity (83.76%) (153.96%) (57.72%)
Return on assets (57.33%) (98.96%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CGTX NRXS Biotechnology median
Revenue growth (TTM) — 65.22% 5.64%
EPS growth (last fiscal year) 62.79% 22.13% —
Revenue growth, 5-year CAGR — 13.08% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGTX NRXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.03 3.04 4.73
Net debt to EBITDA 0.78 0.64 0.96

Dividend

Metric CGTX NRXS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric CGTX NRXS Biotechnology median
Market cap 90.68m 97.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack